Neuralink Corp.

Founded in 2016 and based in Fremont, CA, Neuralink Corp. focuses on developing advanced brain-computer interface (BCI) technologies that allow individuals with severe neurological conditions to control devices through thought alone. The company was founded by Elon Musk along with DJ Seo, Kiwoba Allaire, and Max Hodak, with Arjang Zandnia and Baris Aydeniz who all currently occupy executive roles within the company. In July 2025, Neuralink Corp.

raised an undisclosed amount of venture funding from CoreNest. Neuralink's core offerings center around its brain-computer interface (BCI) technology that translates neural signals into actionable commands. This innovative solution enables individuals with severe neurological conditions, such as spinal cord injuries and amyotrophic lateral sclerosis (ALS), to interact with computers and control robotic limbs using their thoughts. The devices, implanted through minimally invasive surgical techniques, are currently being utilized in various clinical trials, demonstrating their effectiveness in restoring autonomy to users.

The primary clientele includes patients with unmet medical needs, caregivers, and healthcare providers, primarily in North America and Europe, where the technology is being tested and implemented. Additional efforts are aimed at expanding the geographical reach of these solutions to other regions as the technology advances and regulatory approvals are obtained. Neuralink's revenue model is structured around the commercialization of its BCI technology, primarily through clinical trials and eventual sales to healthcare institutions and end-users. The transactions involve the provision of implantable devices and associated services directly to clients, which include hospitals and rehabilitation centers.

Revenue is generated as these institutions procure Neuralink’s products for clinical and therapeutic applications. The pricing structure for individual devices and the associated services is designed to align with existing medical technology pricing standards, yet specific pricing details are proprietary. As the company advances its technology and gains regulatory approvals, it is expected to expand into direct-to-consumer sales, thereby broadening its revenue streams. Neuralink plans to leverage recent funding to accelerate the development of its innovative BCI technology and expand its market presence.

Upcoming products are focused on enhancing device capabilities, with plans for a launch in the coming years pending regulatory approvals. The company will use the July 2025 funding to advance its development of brain-computer interfaces that enable direct device control through neural activity.